Instrument number PB 67 of 2008
Amendment special arrangements under subsection 100(1) of the National Health Act 1953
I, ANDREW MITCHELL, Acting Assistant Secretary, Pharmaceutical Evaluation Branch, Department of Health and Ageing, delegate of the Minister for Health and Ageing, make this instrument under subsection 100(1) of the National Health Act 1953.
Dated 3 JUNE 2008
ANDREW MITCHELL
Acting Assistant Secretary
Pharmaceutical Evaluation Branch
Department of Health and Ageing
Amendment Special Arrangements — Chemotherapy Pharmaceuticals Access Program
1 Commencement
This instrument commences on 1 July 2008.
2 Amendment of PB 93 of 2007
Schedule 1 amends PB 93 of 2007.
Schedule 1 Amendments
[1] Schedule 2, in all instances where Hospira Australia Pty Ltd appears in the column headed “Brand”
omit:
Hospira Australia Pty Ltd
and substitute:
Hospira Pty Limited
[2] Schedule 2, items dealing with Folinic acid
omit from the column headed “Brand” (wherever occurring):
Leucovorin Calcium (Hospira Australia Pty Ltd)
and substitute:
Leucovorin Calcium (Hospira Pty Limited)
[3] Schedule 4, item dealing with Bleomycin
omit from the column headed “Brand”:
Hospira Australia Pty Ltd
and substitute:
Hospira Pty Limited
[4] Schedule 4, item dealing with Folinic acid in the form Injection containing calcium folinate equivalent to 50 mg folinic acid in 5 mL
omit from the column headed “Brand”:
Leucovorin Calcium (Hospira Australia Pty Ltd)
and substitute:
Leucovorin Calcium (Hospira Pty Limited)